Latest research on Docetaxel

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.

Latest findings

In our example, Erlotinib and Gefitinib were frequently lumped together in EGFR TYROSINE kinase inhibitors and Docetaxel and Pemetrexed were lumped together in monochemotherapy. [source, 2016]
From July 2010 until April 2012, 250 women participated in the multicenter phase III NEOZOTAC trial, randomizing between TAC chemotherapy (75 mg/m2 Docetaxel, 50 mg/m2 Doxorubicin, and 500 mg/m2 Cyclophosphamide) with or without Zoledronic acid (4 mg within 24 hours after chemotherapy). [source, 2016]
The patient received one cycle of Docetaxel combined with Cisplatin as sixth-line chemotherapy. [source, 2016]
These 2-ME analogues were probed in combination with other drugs, for example: Docetaxel in breast cancer (28) or Paclitaxel in head and neck squamous cell carcinoma with good results (45). [source, 2016]
In both the FAS and PAS (respectively), Paclitaxel (26% and 25%), Docetaxel (17% and 18%), trastuzumab (14% and 11%), Vinorelbine (12% and 11%), and Capecitabine (9% and 11%) were the most commonly used agents in “non-standard” regimens. [source, 2016]
All the patients with prostate cancer in the FAS and the PAS (n=82 and n=39, respectively) received “non-standard” regimens; in these, Docetaxel (67% and 59%) and cabazitaxel (16% and 26%) were the most commonly used agents. [source, 2016]
Amrubicin [33], Docetaxel [34], and S-1 [16, 35, 36] were reported to be effective for thymic carcinoma. [source, 2016]
Additional inclusion criteria for the chemotherapy group were the patients 1) in whom chemotherapy was administrated in first-line and/or second-line treatment; 2) in whom at least two cycles of cisplatin/pemetrexed or carboplatin/paclitaxel combined regimens in first-line treatment; 3) in whom at least two cycles of single or combined regimens including Docetaxel, pemetrexed, Gemcitabine, and platinum in second-line treatment; and 4) without any anti-EGFR therapy before the occurrence of BM. [source, 2016]
Multiple inhibitors of these pathways including bevacizumab, Gefitinib, Docetaxel, Rapamycin and everolimus etc. are either in clinical trials or are presently in the market. [source, 2016]
Cisplatin, Carboplatin, Docetaxel, Vinorelbine, Gemcitabine, Gefitinib and Erlotinib were obtained from SellekChem. [source, 2016]